These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30967632)

  • 61. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E
    Dtsch Med Wochenschr; 2013 Feb; 138(7):331-6. PubMed ID: 23393003
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Real-time bioluminescence imaging of polycythemia vera development in mice.
    Ma Y; Zhao S; Zhu J; Bettano KA; Qu X; Marshall CG; Young JR; Kohl NE; Scott ML; Zhang W; Wang Y
    Biochim Biophys Acta; 2009 Nov; 1792(11):1073-9. PubMed ID: 19715759
    [TBL] [Abstract][Full Text] [Related]  

  • 63. JAK2V617F mutation and spontaneous megakaryocytic or erythroid colony formation in patients with essential thrombocythaemia (ET) or polycythaemia vera (PV).
    Mustjoki S; Borze I; Lasho TL; Alitalo R; Pardanani A; Knuutila S; Juvonen E
    Leuk Res; 2009 Jan; 33(1):54-9. PubMed ID: 18760472
    [TBL] [Abstract][Full Text] [Related]  

  • 64. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
    Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
    Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Polycythemia vera is not initiated by JAK2V617F mutation.
    Nussenzveig RH; Swierczek SI; Jelinek J; Gaikwad A; Liu E; Verstovsek S; Prchal JF; Prchal JT
    Exp Hematol; 2007 Jan; 35(1):32-8. PubMed ID: 17198871
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [The impact of autophagy on proliferation of HEL cells and hematopoietic cells of polycythemia vera patients with JAK2 V617F mutation].
    Dong L; Shen X; Wei W; Shi W; Zhang G; Cao W; Li D
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jun; 36(6):520-5. PubMed ID: 26134021
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
    Lu X; Levine R; Tong W; Wernig G; Pikman Y; Zarnegar S; Gilliland DG; Lodish H
    Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18962-7. PubMed ID: 16365288
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
    Kesarwani M; Kincaid Z; Gomaa A; Huber E; Rohrabaugh S; Siddiqui Z; Bouso MF; Latif T; Xu M; Komurov K; Mulloy JC; Cancelas JA; Grimes HL; Azam M
    Nat Med; 2017 Apr; 23(4):472-482. PubMed ID: 28319094
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.
    Pardanani A; Lasho TL; Finke C; Hanson CA; Tefferi A
    Leukemia; 2007 Sep; 21(9):1960-3. PubMed ID: 17597810
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
    Tefferi A
    Hematology Am Soc Hematol Educ Program; 2006; ():240-5. PubMed ID: 17124067
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
    Meyer T; Ruppert V; Görg C; Neubauer A
    Int J Hematol; 2010 Jan; 91(1):117-20. PubMed ID: 20013324
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET).
    Zhao S; Zhang X; Xu Y; Feng Y; Sheng W; Cen J; Wu D; Han Y
    Int J Med Sci; 2016; 13(1):85-91. PubMed ID: 26917989
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 76. After 10years of JAK2V617F: Disease biology and current management strategies in polycythaemia vera.
    Grinfeld J; Godfrey AL
    Blood Rev; 2017 May; 31(3):101-118. PubMed ID: 27884555
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Dasatinib inhibits progenitor cell proliferation from polycythaemia vera.
    Wappl M; Jaeger E; Streubel B; Gisslinger H; Schwarzinger I; Valent P; Oehler L
    Eur J Clin Invest; 2008 Aug; 38(8):578-84. PubMed ID: 18717827
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.
    Yan D; Jobe F; Hutchison RE; Mohi G
    Leukemia; 2015 Oct; 29(10):2050-61. PubMed ID: 26044284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.